Merck & Co Inc (MRK)

MRK on New York Consolidated

59.75USD
26 Nov 2014
Price Change (% chg)

$0.41 (+0.69%)
Prev Close
$59.34
Open
$59.70
Day's High
$59.77
Day's Low
$59.35
Volume
6,280,816
Avg. Vol
10,590,953
52-wk High
$61.33
52-wk Low
$47.61

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.33
Market Cap (Mil.): $170,339.70
Shares Outstanding (Mil.): 2,850.87
Dividend: 0.45
Yield (%): 3.01

Financials

  MRK Industry Sector
P/E (TTM): 32.75 37.83 38.74
EPS (TTM): 1.82 -- --
ROI: 6.72 17.93 17.27
ROE: 11.63 18.73 18.18
Search Stocks

Merck buys rights to NewLink's experimental Ebola vaccine

- Merck & Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine against the Ebola virus.

24 Nov 2014

UPDATE 2-Merck buys rights to NewLink's experimental Ebola vaccine

(Adds terms of deal, details on WHO-coordinated trials; updates share movement)

24 Nov 2014

Merck buys rights to NewLink's experimental Ebola vaccine

Nov 24 - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.

24 Nov 2014

Britain begins review to speed access to new drugs

* Innovative Medicines and MedTech Review to report in 2015

20 Nov 2014

Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.

17 Nov 2014

UPDATE 1-Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO, Nov 17 - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.

17 Nov 2014

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Updates with closing prices)

17 Nov 2014

Regeneron drug highly effective for those who can't take statins: study

CHICAGO - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

17 Nov 2014

Regeneron drug highly effective for those who can't take statins -study

CHICAGO, Nov 17 - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

17 Nov 2014

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Recasts, adds quotes, detail)

17 Nov 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks